Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 24.4% in the morning session after the company reported ...
By Mariam Sunny and Michael Erman Feb 26 (Reuters) - Novavax raised its adjusted revenue forecast for 2026 on Thursday, ...
Novavax’s alliance with Sanofi came at an opportune time for the beleaguered vaccine developer. Its protein-based Covid-19 vaccine never reached the revenue highs achieved by the messenger RNA ...
Under the non-exclusive agreement, Pfizer will utilize Novavax’s Matrix-M adjuvant in products across two disease areas, with Novavax receiving a $30 million upfront payment. Additionally, the ...
Hosted on MSN
Novavax Stock Suffers Sharpest Drop In Months After $225M Debt Deal; Retail Still Leans Bullish
Novavax slid Thursday in its worst session in more than four months after laying out plans to refinance $225 million of debt, a move that piled onto fresh concerns from a Bank of America downgrade and ...
TD Cowen 46th Annual Health Care Conference March 3, 2026 2:30 PM ESTCompany ParticipantsJohn Jacobs - President, CEO ...
GAITHERSBURG, Md., Oct. 7, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the marketing authorization for its COVID-19 vaccine, Nuvaxovid® to Sanofi, in the European ...
Vaccine biotechnology company Novavax (NASDAQ:NVAX) in Q3 CY2025, but sales fell by 16.6% year on year to $70.45 million. The company expects the full year’s revenue to be around $1.05 billion, close ...
Novavax reported fourth-quarter earnings of 11 cents, a shift from a loss of 51 cents a year ago. evenue for the fourth quarter was $147 million, a 67% year-over-year increase. Novavax on Thursday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results